- 1 Etymology
- 2 Signs and symptoms
- 3 Epidemiology
- 4 Diagnosis
- 5 Pathophysiology
- 6 Treatment
- 6.1 Clinical practice guidelines
- 6.2 Systematic reviews
- 6.3 Disease modifying anti-rheumatic agents
- 6.4 Anti-inflammatory drugs
- 6.5 Analgesics
- 6.6 Non-drug treatments
- 6.7 Historical treatments
- 6.8 Investigational treatments
- 7 Prognosis
- 8 History
- 9 References
Rheumatoid arthritis (RA) is traditionally considered a chronic, inflammatory autoimmune disorder that causes the immune system to attack the joints. It is a disabling and painful inflammatory condition, which can lead to substantial loss of mobility due to pain and joint destruction. RA is a systemic disease, often affecting extra-articular tissues throughout the body including the skin, blood vessels, heart, lungs, and muscles. About 60% of RA patients are unable to work 10 years after the onset of their disease.
Rheumatoid arthritis appears to have been described in paintings more than a century before the first detailed medical description of the condition in 1800 by Landre-Beauvais.
The name is derived from the Greek. Rheumatos means "flowing", and this initially gave rise to the term 'rheumatic fever', an illness that can follow throat infections and which includes joint pain. The suffix -oid means "resembling", i.e. resembling rheumatic fever. Arthr means "joint" and the suffix -itis, a "condition involving inflammation". Thus rheumatoid arthritis was a form of joint inflammation that resembled rheumatic fever.
Signs and symptoms
The inflammatory activity leads to erosion and destruction of the joint surface as the pathology progresses, which impairs their range of movement and leads to deformity. The fingers are typically deviated towards the little finger (ulnar deviation) and can assume unnatural shapes. Classical deformities in rheumatoid arthritis are the Boutonniere deformity (Hyperflexion at the proximal interphalangeal joint with hyperextension at the distal interphalangeal joint), swan neck deformity (Hyperextension at the proximal interphalangeal joint, hyperflexion at the distal interphalangeal joint). The thumb may develop a "Z-Thumb" deformity with fixed flexion and subluxation at the metacarpophalangeal joint, and hyperextension at the IP joint.
Rheumatoid arthritis versus osteoarthritis
The symptoms that distinguish rheumatoid arthritis from other forms of arthritis are inflammation and soft-tissue swelling of many joints at the same time (polyarthritis). The joints are usually affected initially asymmetrically and then in a symmetrical fashion as the disease progresses. The pain generally improves with use of the affected joints, and there is usually stiffness of all joints in the morning that lasts over 1 hour. Thus, the pain of rheumatoid arthritis is usually worse in the morning compared to the classic pain of osteoarthritis where the pain worsens over the day as the joints are used.
Extra-articular manifestations also distinguish this disease from osteoarthritis (hence it is a multisystemic disease). For example, most patients also suffer with anemia, either as a consequence of the disease itself (anaemia of chronic disease) or as a consequence of gastrointestinal bleeding as a side effect of drugs used in treatment, especially NSAIDs (non-steroidal anti-inflammatory drugs) used for analgesia. Hepatosplenomegaly may occur with concurrent leukopaenia (Felty's syndrome), and lymphocytic infiltration may affect the salivary and lacrimal glands (Sjögren's syndrome). Pericarditis, pleurisy, alveolitis, scleritis and subcutaneous nodules are other features associated with rheumatoid arthritis.
The most prominent cutaneous manifestations of rheumatoid arthritis are rheumatoid nodules and vasculitis.
Rheumatoid arthritis is associated with a variety of forms of vasculitis. A benign form occurs as microinfarcts around the nailfolds. More severe forms include livedo reticularis, which is a network (reticulum) of erythematous to purplish discoloration of the skin due to the presence of an obliterative cutaneous capillaropathy. (This rash is also otherwise associated with the antiphospholipid-antibody syndrome, a hypercoagulable state linked to antiphospholipid antibodies and characterized by recurrent vascular thrombosis and second trimester miscarriages.
Other cutaneous manifestations
Rheumatoid arthritis is rarely associated with pyoderma gangrenosum, a necrotizing, ulcerative, noninfectious neutrophilic dermatosis. Other complications include erythema nodosum, lobular panniculitis, atrophy of digital skin, palmar erythema, diffuse thinning of the skin (rice paper skin), and skin fragility.
The cutaneous (strictly speaking subcutaneous) feature most characteristic of rheumatoid arthritis is the rheumatoid nodule. The initial pathologic process in nodule formation is unknown but is thought to be related to small-vessel inflammation. The mature lesion is defined by an area of central necrosis surrounded by palisading macrophages and fibroblasts and a cuff of cellular connective tissue and chronic inflamed cells. The typical rheumatoid nodule may be a few millimetres to a few centimetres in diameter and is usually found over bony prominences, such as the olecranon, the calcaneum at the Achilles tendon insertion, the metacarpophalangeal joints, or other areas that sustain repeated mechanical stress. Nodules are associated with a positive RF titer and severe erosive arthritis. They can rarely occur throughout the body in internal organs.
- The lungs may become involved as a part of the primary disease process or as a consequence of therapy. If such is the case, fibrosis may occur spontaneously or as a consequence of therapy (for example methotrexate). In addition, Caplan's nodules are found as are pulmonary effusions.
- Amyloidosis in the kidney can occur.
- Possible complications that may arise include: pericarditis, endocarditis, left ventricular failure, valvulitis and fibrosis. The risk of cardiovascular, specifically myocardial infarction (heart attack) or congestive heart failure are greater in individuals with RA. Over 1/3 of deaths of people with RA are directly attributable to cardiovascular death.
- Keratoconjunctivitis sicca (dry eyes), scleritis, episcleritis and scleromalacia are possible complications of rheumatoid arthritis.
- Peripheral neuropathy and mononeuritis multiplex may occur. The most common problem is carpal tunnel syndrome due to compression of the median nerve by swelling around the wrist. Atlanto-axial subluxation can occur, owing to erosion of the odontoid process and or/transverse ligaments in the cervical spine's connection to the skull. Such an erosion (>3mm) can give rise to vertebrae slipping over one another and compressing the spinal cord. At first the patient experiences clumsiness but without due care this can progress to quadriplegia.
- Osteoporosis classically occurs in RA around inflamed joints. It is postulated to be partially caused by inflammatory cytokines.
- The incidence of lymphoma is increased in RA as it is in most autoimmune conditions.
The incidence of RA is in the region of 3 cases per 10,000 population per annum. Onset is uncommon under the age of 15 and from then on the incidence rises with age until the age of 80. The prevalence rate is 1%, with women affected three to five times as often as men. It is 4 times more common in smokers than non-smokers. Some Native American groups have higher prevalence rates (5-6%) and black persons from the Caribbean region have lower prevalence rates. First-degree relatives prevalence rate is 2-3% and disease concordance in monozygotic twins is approximately 15-20%.
It is strongly associated with the inherited tissue type Major histocompatibility complex (MHC) antigen HLA-DR4 (most specifically DR0401 and 0404) — hence family history is an important risk factor.
When RA is suspected, immunologic tests of the patient's blood are required.
The rheumatoid factor (RF) blood test is a blood test for an autoantibody against gamma-chain immunoglobulins and may help diagnose RA. Meta-analyses of the accuracy of the rheumatoid factor found:
Thus, a negative RF does not rule out RA.
Anti-cyclic citrullinated peptide (anti-CCP) antibody
Because of the low specificity of the RF, a new test is for the presence of Anti–citrullinated peptide antibodies (ACPA). These antibodies include anti-cyclic citrullinated peptide (anti-CCP) antibodies. A meta-analysis of the accuracy of the anti-CCP found:
The cause of RA is not known. Once triggered, the immune response causes inflammation of the synovium, leading to edema, vasodilation and infiltration by activated T-cells (mainly CD4 in nodular aggregates and CD8 in diffuse infiltrates). Early and intermediate molecular mediators of inflammation include tumor necrosis factor alpha (TNF-α), interleukins IL-1, IL-6, IL-8 and IL-15, transforming growth factor beta, fibroblast growth factor and platelet-derived growth factor. Synovial macrophages and dentritic cells function as antigen presenting cells by expressing MHC class II molecules, leading to the production of immunoglobins, rheumatoid factors of the IgG and IgM class and complement components by B-Lymphocytes. The disease progresses in concert with formation of granulation tissue at the edges of the synovial lining (pannus) with extensive angiogenesis and production of enzymes that cause tissue damage. Once the inflammatory reaction is established, the synovium thickens, the cartilage and the underlying bone begins to disintegrate and evidence of joint destruction accrues.
The risk decreased as the consumption of alcohol increased from light to moderate levels. 
Inheritance and molecular basis
Autoimmune diseases require that the affected individual have a defect in the ability to distinguish foreign molecules from the body's own. There are markers on many cells that confer this self-identifying feature. However, some classes of markers allow for RA to happen. The major histocompatibility complex encodes the cell-surface proteins known as the human leukocyte antigens (HLAs) that are responsible for self-identification. In some populations, some HLA genotypes are associated with RA. Among anglo patients with RA, 70% express HLA-DR4, compared to 28% of patients without RA. In Native Americans, a similar association occurs with HLA-DR9.
Genes outside of the HLA region are also associated with RA. A single-nucleotide polymorphism (SNP) of the STAT4 gene is associated with both rheumatoid arthritis and systemic lupus erythematosus (SLE).
The role of infections
Various infections have been suspected of contributing to RA. Examples are Mycoplasma, Erysipelothrix, Epstein-Barr virus, Parvovirus B19 and rubella have been suspected but never supported in epidemiological studies. Although tetracycline antibiotics have been used to treat RA, these antibiotics may have nonspecific immunomodulator effects.
There is no known cure for rheumatoid arthritis. However, many different types of treatment can be used to alleviate symptoms. Pharmacological treatment of RA can be divided into disease-modifying antirheumatic drugs (DMARDs), anti-inflammatory agents and analgesics.
Treating to specific goals or targets may be most effective.
Clinical practice guidelines
Disease modifying anti-rheumatic agents
The term Disease Modifying Anti-Rheumatic Agent or Disease Modifying Anti-Rheumatic Drug (DMARD) refers to agents that show evidence of processes thought to underlie the disease, such as a raised erythrocyte sedimentation rate, reduced haemoglobin level, raised rheumatoid factor level and more recently, raised C-reactive protein level. "Agent" became more preferred than "drug" to be more inclusive of the various biological treatments.
More recently, the working definition is an agent that reduces the rate of damage to bone and cartilage. For other areas of medicine, disease-modifying treatment is coming into use for drugs that can stop or reverse a progressive disease.
Rationale for early use
There is an increasing recognition amongst rheumatologists that permanent damage to the joints occurs at a very early stage in the disease. In the past the strategy used was to start with just an anti-inflammatory drug, and assess progression clinically and using X-rays. If there was evidence that joint damage was starting to occur then a more potent DMARD would be prescribed. Tools such as ultrasound and MRI are more sensitive methods of imaging the joints and have demonstrated that joint damage occurs much earlier and in more patients than was previously thought. Patients with normal X-rays will often have erosions detectable by ultrasound that X ray could not demonstrate.
Using DMARDs early reduces structural joint damage. In the early stage of the disease, the joints are increasingly infiltrated by cells of the immune system that signal to one another and are thought to set up self-perpetuating chronic inflammation. Interrupting this process as early as possible with an effective DMARD (such as methotrexate) appears to improve the outcome from the RA for years afterwards. Delaying therapy for as little as a few months after the onset of symptoms can result in worse outcomes in the long term..
Types of DMARDS
Many rheumatologists consider methotrexate to be the most important and useful DMARD, largely because of lower rates of stopping the drug through toxicity; however, a systematic review was not able to conclude that any one or combination of DMARDs was preferable.
DMARDs can be further subdivided into traditional small molecular mass drugs synthesised chemically and newer 'biological' agents produced through genetic engineering.
Small molecular mass drugs
Traditional small molecular mass drugs:
- ciclosporin (cyclosporine A)
- gold drugs
- methotrexate (MTX)
- sulfasalazine (SSZ)
The most important and most common adverse events relate to liver and bone marrow toxicity (MTX, SSZ, leflunomide, azathioprine, gold compounds, D-penicillamine), renal toxicity (cyclosporine A, parenteral gold salts, D-penicillamine), pneumonitis (MTX), allergic skin reactions (gold compounds, SSZ), autoimmunity (D-penicillamine, SSZ, minocycline) and infections (azathioprine, cyclosporine A). Hydroxychloroquine may cause ocular toxicity, although this is rare, and because hydroxychloroquine does not affect the bone marrow or liver it is often considered to be the DMARD with the least toxicity. Unfortunately hydroxychloroquine is not very potent, and for most patients hydroxychloroquine alone is insufficient to control symptoms.
- Cytokine inhibors
- Tumor necrosis factor-alpha (TNFα) cytokine inhibitors
- Interleukin-1 cytokine blockers
- Anakinra. Anakinra is currently not recommended by National Institute for Health and Clinical Excellence.
- Lymphocyte inhibitors
Anti-inflammatory agents include:
Severely affected joints may require joint replacement surgery, such as knee replacement.
Historical treatments for this condition have included: gold salts, RICE, acupuncture, apple diet, nutmeg, some light exercise every now and then, nettles, bee venom, prayer, copper bracelets, rhubarb diet , rest, extractions of teeth, fasting, honey, vitamins, insulin, magnets, and electric convulsion therapy (ECT). Cortisone therapy has offered relief to many patients in the past, but its long-term effects have been deemed undesirable.
Recent research indicates that cytokines, a group of chemicals that are produced by various cells in the body, may be responsible for generating the response of chronic pain associated with Rheumatoid Arthritis. Medications that affect the release of cytokines or block the action of cytokines may reduce the response of chronic pain. Thalidomide, is being evaluated for its effect in treating chronic pain associated with Arachnoiditis.
An experimental treatment known as enzyme potentiated desensitization (EPD) is now under development for the treatment of rheumatoid arthritis and other autoimmune diseases. EPD uses dilutions of allergen (in this case type 2 collagen) and an enzyme, β-glucuronidase, to which T-regulatory lymphocytes respond by favouring desensitization, rather than sensitization. Initial results are encouraging  but the treatment is still at an early stage of development.
For certain patients shown to be unresponsive to or intolerant of DMARDs, the Prosorba column blood filtering device appeared promising after the FDA approved it for treatment of RA in 1999 . The Prosorba column employs protein A covalently bound to an inert silica matrix. The protein A binds immunoglobulin G (IgG) and circulating immune complexes (CIC). This blocks antigens responsible for autoimmune joint deterioration. 
The course of the disease varies greatly from patient to patient. Some patients have mild short-term symptoms, but in most the disease is progressive for life. Around 20%-30% will have subcutaneous nodules (known as rheumatoid nodules); this is associated with a poor prognosis.
- Daily living activities are impaired in most patients.
- After 5 years of disease, approximately 33% of patients will not be working
- After 10 years, approximately half will have substantial functional disability.
- Poor prognostic factors include persistent synovitis, early erosive disease, extra-articular findings (including subcutaneous rheumatoid nodules), positive serum RF findings, positive serum anti-CCP autoantibodies, carriership of HLA-DR4 "Shared Epitope" alleles, family history of RA, poor functional status, socioeconomic factors, elevated acute phase response (erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]), and increased clinical severity.
Estimates of the life-shortening effect of RA vary; most sources cite a lifespan reduction of 5 to 10 years; the National Institutes of Health has estimated a lifespan reduction of 10 to 20 years. According to the UK's National Rheumatoid Arthritis Society, "Young age at onset, long disease duration, the concurrent presence of other health problems (called co-morbidity), and characteristics of severe RA – such as poor functional ability or overall health status, a lot of joint damage on x-rays, the need for hospitalisation or involvement of organs other than the joints – have been shown to associate with higher mortality". Positive responses to treatment may indicate a better prognosis. A 2005 study by the Mayo Clinic noted that RA patients suffer a doubled risk of heart disease, independent of other risk factors such as diabetes, alcohol abuse, and elevated cholesterol, blood pressure and body mass index. The mechanism by which RA causes this increased risk remains unknown; the presence of chronic inflammation has been proposed as a contributing factor.
To delineate the history of rheumatoid arthritis a researcher must rely on scanty and ambiguous data from old medical literature and buried skeletons. The current consensus is too speculative for the taste of some scholars. Nevertheless a tentative best guess has emerged.
The first known traces of arthritis date back at least as far as 4500 BC. A text dated 123 AD first describes symptoms very similar to rheumatoid arthritis. It was noted in skeletal remains of Native Americans found in Tennessee. In the Old World the disease is vanishingly rare before the 1600s. and on this basis investigators believe it spread across the Atlantic during the Age of Exploration. In 1859 the disease acquired its current name.
A fascinating anomaly has been noticed from investigation of Precolumbian bones. The bones from the Tennessee site show no signs of tuberculosis even though it was prevalent at the time throughout the Americas.Jim Mobley, at Pfizer, has discovered a historical pattern of epidemics of tuberculosis followed by a surge in the number of rheumatoid arthritis cases a few generations later. Mobley attributes the spikes in arthritis to selective pressure caused by tuberculosis. A hypervigilant immune system is protective against tuberculosis at the cost of an increased risk of autoimmune disease.
The art of Peter Paul Rubens may depict the effects of rheumatoid arthritis, for it is presumed that he used his own hands as a model. In his later paintings, his rendered hands show increasing deformity consistent with the symptoms of the disease.
- Johns Hopkins University: Rheumatoid Arthritis
- Dequeker J., Rico H. (1992). "Rheumatoid arthritis-like deformities in an early 16th-century painting of the Flemish-Dutch school". Jama 268: 249-251. PMID 1608144.
- Oxfordjournals - kel011v1
- Aletaha D et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010 Sep; 62:2569. DOI:10.1002/art.27584 http://pubmed.gov/20872595
- Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, Healey L, Kaplan S, Liang M, Luthra H (1988). "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.". Arthritis Rheum 31 (3): 315-24.
- Rheumatoid Factor. Lab Tests Online. American Association for Clinical Chemistry (September 30, 2006). Retrieved on 2006-10-28.
- Nishimura K, Sugiyama D, Kogata Y, et al (2007). "Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis". Ann. Intern. Med. 146 (11): 797–808. PMID 17548411.
- CCP (Cyclic Citrullinated Peptide antibody). Lab Tests Online. American Association for Clinical Chemistry (January 15, 2005). Retrieved on 2006-10-28.
- Whiting, Penny F.; Nynke Smidt, Jonathan A.C. Sterne, Roger Harbord, Anya Burton, Margaret Burke, Rebecca Beynon, Yoav Ben-Shlomo, John Axford, Paul Dieppe (2010-04-06). "Systematic Review: Accuracy of Anti–Citrullinated Peptide Antibodies for Diagnosing Rheumatoid Arthritis". Annals of Internal Medicine 152 (7): 456-464. DOI:10.1059/0003-4819-152-7-201004060-00010. Retrieved on 2010-04-06. Research Blogging.
- Turesson, Carl. Increased Alcohol Intake Associated with Decreased Risk of Developing Rheumatoid Arthritis. (Abstract) Paper presented at the annual European Congress of Rheumatology. Barcelona, Spain. June 13-16, 2007. European League Against Rheumatism, June 15, 2007; Myllykangas-Lusojarvi, R., Aho, K., Kautiainen, H., and Hakala, M. Reduced incidence of alcohol related deaths in subjects with rheumatoid arthritis. Annals of Rheumatoid Diseases, 2000, 59, 75-76; Voight, L., et al. Smoking, obesity, alcohol consumption and the risk of rheumatoid arthritis. Epidemiology, 1994, 5, 525-532
- Smith JB, Haynes MK (2002). "Rheumatoid arthritis--a molecular understanding". Ann. Intern. Med. 136 (12): 908–22. PMID 12069565.
- Remmers EF, Plenge RM, Lee AT, et al (2007). "STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus". N. Engl. J. Med. 357 (10): 977–86. DOI:10.1056/NEJMoa073003. PMID 17804842. Research Blogging.
- Clark HW, Coker-Vann MR, Bailey JS, Brown TM (1988). "Detection of mycoplasmal antigens in immune complexes from rheumatoid arthritis synovial fluids". Annals of allergy 60 (5): 394–8. PMID 3369750.
- Reeta KH, Mediratta PK, Mahajan P, Sharma KK (2002). "Effect of minocycline and tetracycline on immunological responses in experimental animals". Indian journal of medical sciences 56 (11): 553–9. PMID 14510338.
- O'Dell J (2004). "Therapeutic strategies for rheumatoid arthritis.". N Engl J Med 350 (25): 2591-602. PMID 15201416.
- Hasler P (Jun 2006). "Biological therapies directed against cells in autoimmune disease.". Springer Semin Immunopathol 27 (4): 443-56. PMID 16738955.
- Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT et al. (2010). "Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.". Ann Rheum Dis 69 (4): 638-43. DOI:10.1136/ard.2009.123976. PMID 20237123. Research Blogging.
- Saag KG et al. (2008) 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis & Rheumatism
- Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA et al. (2009). "A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.". CMAJ 181 (11): 787-96. DOI:10.1503/cmaj.091391. PMID 19884297. PMC PMC2780484. Research Blogging.
- Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA et al. (2009). "Biologics for rheumatoid arthritis: an overview of Cochrane reviews.". Cochrane Database Syst Rev (4): CD007848. DOI:10.1002/14651858.CD007848.pub2. PMID 19821440. Research Blogging.
- Vital E, Emery P (Sep 15 2005). "Advances in the treatment of early rheumatoid arthritis.". Am Fam Physician 72 (6): 1002, 1004. PMID 16190499.
- Donahue KE, Gartlehner G, Jonas DE, et al (2008). "Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis". Ann. Intern. Med. 148 (2): 124–34. PMID 18025440.
- Kristensen L, Jakobsen A, Bartels E, Geborek P, Bliddal H, Saxne T et al. (2010). "The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials.". Scand J Rheumatol. DOI:10.3109/03009742.2010.491834. PMID 20950126. Research Blogging.
- Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM et al. (2010). "Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.". Ann Rheum Dis 69 (6): 976-86. DOI:10.1136/ard.2009.126573. PMID 20447957. Research Blogging.
- Dentener MA, Wouters EF (2006). "Tumor necrosis factor inhibitors for rheumatoid arthritis.". N Engl J Med 355 (19): 2047-8; author reply 2048. PMID 17099951.
- National Collaborating Centre for Chronic Conditions. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Feb. 35 p. (NICE clinical guideline; no. 79).
- Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al. (2004). "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.". N Engl J Med 350 (25): 2572-81. DOI:10.1056/NEJMoa032534. PMID 15201414. Research Blogging.
- Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C et al. (2006). "Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.". Ann Intern Med 144 (12): 865-76. PMID 16785475.
- Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J et al. (2005). "Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.". N Engl J Med 353 (11): 1114-23. DOI:10.1056/NEJMoa050524. PMID 16162882. Research Blogging.
- Hart FD (1976). "History of the treatment of rheumatoid arthritis". British medical journal 1 (6012): 763–5. PMID 177148.
- BOLAND EW, HEADLEY NE (1951). "Results of long-continued cortisone administration in rheumatoid arthritis". California medicine 74 (6): 416–23. PMID 14848703.
- EPD treatment of rheumatoid arthritis proof of concept results on Epidyme website use of EPD to treat autoimmune diseases.
- Fresenius HemoCare, Inc., "New Hope for Rheumatoid Arthritis Patients," press release, September 17, 1999. Dr. Gerónimo Lluberas is quoted as saying, "It offers a bright new promise to those that are otherwise unresponsive to this dreadful disease." Also see arthritis.about.com 
- [www.nih.gov/about/researchresultsforthepublic/arthritis.pdf Rheumatoid arthritis prognosis]
- Excess mortality in rheumatoid arthritis
- The second largest contributor of mortality is cerebrovascular disease. Increased risk of heart disease in rheumatoid arthritis patients
- Cardiac disease in rheumatoid arthritis
- http://mcclungmuseum.utk.edu/research/renotes/rn-05txt.htm Tennessee Origins of Rheumatoid Arthritis
- http://www.arc.org.uk/newsviews/arctdy/104/bones.htm Bones of Contention
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14528501&dopt=Abstract Unified theory of the origins of erosive arthritis: conditioning as a protective/directing mechanism?
- http://media.www.michigandaily.com/media/storage/paper851/news/2005/02/01/News/Scientist.Finds.Surprising.Links.Between.Arthritis.And.Tuberculosis-1428389.shtml?sourcedomain=www.michigandaily.com&MIIHost=media.collegepublisher.com Scientist finds surprising links between arthritis and tuberculosis
- JAMA article - Rubens and the question of antiquity of rheumatoid arthritis
- http://japan.medscape.com/viewarticle/538251 Did RA travel from New World to Old? The Rubens connection